Sunshine Biopharma Business Summary

Sunshine Biopharma Inc. (SBFM) operates a dual-track pharmaceutical business model that balances immediate revenue generation from generic drug distribution with long-term value creation through proprietary biotechnology R&D. The company generates approximately 97% of its revenue through its Canadian subsidiary, Nora Pharma Inc., which commercializes a portfolio of over 70 generic prescription medicines targeting indications such as oncology, cardiology, and gastroenterology. Its operations are divided into two primary segments: Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter (OTC) Products, the latter of which markets science-based nutritional supplements. Sunshine Biopharma also maintains a high-risk clinical pipeline featuring K1.1 mRNA for liver cancer and SBFM-PL4, a protease inhibitor for SARS-related coronaviruses. In the competitive small-cap landscape, the company sits alongside peers such as Lixte Biotechnology (LIXT), VistaGen Therapeutics (VTGN), and Finch Therapeutics Group (FNCH), distinguishing itself by using its established generics distribution engine to mitigate the capital intensity of its early-stage drug discovery programs. The company is led by founder Dr. Steve N. Slilaty, who serves as Chairman and CEO and maintains approximately 96% of the total voting power. Dr. Slilaty is a veteran molecular biologist with a Ph.D. from the University of Arizona whose scientific pedigree includes the discovery of the S24 class of enzymes and the development of cloning technologies used in the Human Genome Project. The current leadership team includes CFO Camille Sebaaly, Chief Commercial Officer Michel Roy, and Chief Development Officer Malek Chamoun, following the February 2026 resignation of former COO Dr. Abderrazzak Merzouki. The board of directors features independent members such as David Natan and Dr. Rabi Kiderchah, while the company’s institutional investor base includes notable firms such as Citadel Advisors, Morgan Stanley, and UBS Group.